A hypervascular perivascular epithelioid cell tumor of the urinary bladder showing TFE3 immunoreactivity clinically misdiagnosed as paraganglioma in an adolescent patient Authors: Minjie Ou, Chongjun Ji, Jin Wen Published: 2026 ABSTRACT Perivascular epithelioid cell tumor (PEComa) of the urinary bladder is an exceptionally rare mesenchymal neoplasm and may be difficult to diagnose preoperatively. We report a rare case of a hypervascular bladder PEComa with TFE3 expression in an adolescent female that was clinically misdiagnosed as paraganglioma. A 16-year-old girl presented with intermittent gross hematuria. Imaging revealed a hypervascular submucosal bladder mass with marked homogeneous enhancement on computed tomography urography (CTU) and mild-to-moderate uptake on somatostatin receptor imaging, leading to suspicion of paraganglioma and preoperative α-adrenergic blockade. Histopathologic examination after transurethral resection showed epithelioid tumor cells with a low proliferative index. Immunohistochemistry demonstrated nuclear TFE3 positivity and strong cathepsin K expression, while melanocytic and neuroendocrine markers were negative, supporting a diagnosis of PEComa showing TFE3 immunoreactivity. The patient remains disease-free at six months of follow-up. This case highlights an important diagnostic pitfall of hypervascular bladder tumors mimicking paraganglioma, particularly in adolescent patients. Introduction Perivascular epithelioid cell tumor (PEComa) is a rare mesenchymal neoplasm characterized by distinctive perivascular epithelioid cells that typically co-express melanocytic and smooth muscle markers [1, 2]. PEComas have been reported in a wide range of anatomic sites, most commonly in the kidney, uterus, and soft tissue. However, the urinary bladder is exceedingly uncommon [2–4]. Owing to their rarity, broad morphologic spectrum, and lack of specific clinical manifestations, bladder PEComas often present significant diagnostic challenges for both clinicians and pathologists [2, 3]. With advances in molecular pathology, PEComas are increasingly recognized as a heterogeneous group, comprising at least two distinct molecular subsets. One subset is associated with alterations in the tuberous sclerosis complex (TSC1/TSC2) and activation of the mTOR signaling pathway, while another is characterized by TFE3 gene rearrangements and is considered molecularly distinct [1, 5, 6]. TFE3-rearranged PEComas have been reported to demonstrate unique morphologic features and immunophenotypic profiles, and some studies suggest they may exhibit different clinical behavior compared with conventional TSC-associated PEComas [4–6]. However, in routine diagnostic practice, TFE3 immunohistochemical positivity does not invariably correlate with the presence of a molecularly confirmed TFE3 gene rearrangement, thereby introducing additional complexity into tumor classification and risk assessment [7, 8]. Diagnosis in the bladder requires careful morphologic characterization and exclusion of other entities in the differential diagnosis, such as neuroendocrine neoplasms including paraganglioma, due to overlapping nested epithelioid architecture and vascular features. The immunophenotypic profile, including positivity for cathepsin K and variable expression of melanocytic markers, along with potential TFE3 expression or rearrangement in a subset of cases, aids in distinguishing PEComa from mimics [6]. Although immunohistochemical studies, including cathepsin K positivity and variable melanocytic marker expression—with TFE3 nuclear positivity in a subset—aid in establishing the diagnosis, the distinction may remain challenging preoperatively when molecular confirmation is not available. Herein, we report a rare case of bladder PEComa in an adolescent female that was clinically suspected to be paraganglioma preoperatively, requiring α-adrenergic blockade, but ultimately demonstrated TFE3 immunohistochemical positivity, cathepsin K expression, and absence of classic melanocytic and neuroendocrine markers without molecular confirmation of TFE3 rearrangement. This case highlights the clinical diagnostic pitfalls of bladder PEComa showing TFE3 immunoreactivity and underscores the importance of comprehensive pathologic evaluation in hypervascular bladder tumors clinically mimicking paraganglioma. Case Presentation. A 16-year-old female was referred to our institution for evaluation of a bladder mass that had been detected one year earlier. One year prior to admission, she experienced two episodes of gross hematuria, both occurring one day before menstruation. No lower urinary tract symptoms, such as dysuria, urinary frequency, urgency, or pelvic pain were reported. She had no history of paroxysmal hypertension, headache, palpitations, diaphoresis, or syncope. At the time of initial presentation to an outside hospital, a cystoscopic biopsy of the bladder lesion was performed. Histopathologic evaluation suggested glandular cystitis, and the patient’s family declined definitive surgical intervention in favor of close surveillance. During follow-up, serial imaging demonstrated progressive enlargement of the bladder lesion. Repeat ultrasonography revealed a solid mass arising from the right posterior bladder wall, measuring approximately 3.5 × 2.9 × 2.1 cm, with a broad base, irregular contour, and rich intralesional blood flow on color Doppler imaging (Fig. 1). Contrast-enhanced CTU showed a well-circumscribed submucosal soft-tissue mass with marked and homogeneous enhancement (Fig. 2), without evidence of pelvic lymphadenopathy or distant metastasis. Fig. 1Ultrasonographic findings of the bladder lesion Ultrasonographic findings of the bladder lesion Gray-scale ultrasonography demonstrates a solid mass arising from the right posterior wall of the urinary bladder with a broad base and irregular contour. Color Doppler imaging shows abundant intralesional blood flow, indicating a hypervascular tumor. Fig. 2Contrast-enhanced CT urography of the bladder tumor Contrast-enhanced CT urography of the bladder tumor Contrast-enhanced computed tomography urography (CTU) reveals a well-circumscribed submucosal soft-tissue mass located in the right posterior wall of the urinary bladder, showing marked and homogeneous enhancement in the arterial phase, without evidence of pelvic lymphadenopathy or distant metastasis. Given the hypervascular nature and location of the lesion, a bladder paraganglioma was considered clinically. SPECT/CT fusion imaging demonstrated mild to moderate somatostatin receptor uptake in the right posterior bladder wall lesion (Fig. 3). However, plasma metanephrine, normetanephrine, and other endocrine parameters were within normal limits, and the patient remained clinically asymptomatic. Fig. 3Somatostatin receptor imaging of the bladder lesion Somatostatin receptor imaging of the bladder lesion SPECT/CT fusion imaging demonstrates mild to moderate somatostatin receptor uptake in the right posterior bladder wall lesion (crosshair), which raised the clinical suspicion of bladder paraganglioma. After adequate preoperative α-adrenergic blockade, the patient underwent transurethral resection of the bladder tumor under general anesthesia. Intraoperatively, a solid mass approximately 4 cm in diameter was identified at the right side of the bladder trigone, adjacent to the right ureteral orifice. The tumor was completely resected with adequate depth extending to the muscular layer. The perioperative course was uneventful. Histopathologic examination revealed sheets of epithelioid tumor cells infiltrating the lamina propria (Fig. 4). The tumor cells exhibited eosinophilic to clear cytoplasm with relatively uniform nuclei, inconspicuous nucleoli, and no significant cytologic atypia. The Ki-67 proliferation index was approximately 1%. Immunohistochemical analysis demonstrated focal weak positivity for smooth muscle actin (SMA), strong cytoplasmic positivity for cathepsin K (Fig. 5), and strong nuclear positivity for TFE3 (Fig. 6). The tumor cells were negative for desmin, AE1/AE3, HMB45, Melan-A, chromogranin A, synaptophysin (Fig. 7), S-100, CD34, and α-inhibin. SDHB expression was retained. Based on the morphologic and immunophenotypic findings, neuroendocrine neoplasms such as paraganglioma were considered unlikely. The overall features raised the possibility of PEComa showing TFE3 immunoreactivity. Molecular testing for TFE3 gene rearrangement was not performed because the test was not routinely available at our institution during the patient’s treatment period. The patient recovered well postoperatively. At nearly six months of outpatient follow-up, she remains asymptomatic with no evidence of local recurrence or metastatic disease on clinical and imaging evaluation. Fig. 4Hematoxylin and eosin (H&E) staining shows sheets of epithelioid tumor cells with eosinophilic to clear cytoplasm and uniform nuclei infiltrating the lamina propria (Scale bar: 250 μm) Hematoxylin and eosin (H&E) staining shows sheets of epithelioid tumor cells with eosinophilic to clear cytoplasm and uniform nuclei infiltrating the lamina propria (Scale bar: 250 μm) Fig. 5The tumor cells exhibit intense and diffuse cytoplasmic expression of cathepsin K (Scale bar: 500 μm) The tumor cells exhibit intense and diffuse cytoplasmic expression of cathepsin K (Scale bar: 500 μm) Fig. 6Immunohistochemical staining reveals strong and diffuse nuclear positivity for TFE3 in the tumor cells (Scale bar: 250 μm) Immunohistochemical staining reveals strong and diffuse nuclear positivity for TFE3 in the tumor cells (Scale bar: 250 μm) Fig. 7Immunohistochemical staining for synaptophysin (Syn) is completely negative, supporting the exclusion of a neuroendocrine phenotype (Scale bar: 500 μm) Immunohistochemical staining for synaptophysin (Syn) is completely negative, supporting the exclusion of a neuroendocrine phenotype (Scale bar: 500 μm) Discussion Urinary bladder PEComa is an exceptionally rare mesenchymal neoplasm, and its diagnosis remains challenging because of its broad morphologic spectrum and the lack of specific clinical manifestations. In the present case, a hypervascular submucosal bladder mass in an adolescent female demonstrated marked homogeneous enhancement on CT urography and mild-to-moderate uptake on somatostatin receptor imaging, which strongly suggested bladder paraganglioma and led to an initial clinical misdiagnosis and preoperative α-adrenergic blockade. However, postoperative histopathologic evaluation revealed sheets of epithelioid tumor cells in the lamina propria with a low proliferative index, and immunohistochemistry showed nuclear TFE3 positivity and strong cathepsin K expression, while melanocytic markers (HMB45 and Melan-A) and neuroendocrine markers (chromogranin A and synaptophysin) were negative. These findings were considered suggestive of a PEComa showing TFE3 immunoreactivity and highlight the potential diagnostic pitfall of hypervascular bladder tumors that clinically and radiologically mimic paraganglioma. In our case, the preoperative working diagnosis was bladder paraganglioma, mainly based on a hypervascular submucosal bladder mass with marked and homogeneous enhancement on CT urography [9]. Additionally, mild-to-moderate somatostatin receptor uptake on SPECT/CT fusion imaging further supported the suspicion of a neuroendocrine tumor [9]. Although the patient had no typical catecholamine-related symptoms and urinary/plasma metanephrine levels were within normal limits, paraganglioma could not be completely excluded because some paragangliomas may present with minimal or atypical endocrine manifestations, including incidental identification on imaging [10, 11]. Therefore, preoperative α-adrenergic blockade was administered to reduce the risk of intraoperative hemodynamic instability [12]. Histologically, the tumor showed sheets of epithelioid cells infiltrating the lamina propria with a very low proliferative index (Ki-67 ≤ 1%). The immunophenotype was not supportive of paraganglioma, as neuroendocrine markers (chromogranin A and synaptophysin) were negative, and SDHB expression was retained. In contrast, the tumor demonstrated strong nuclear TFE3 positivity and intense cathepsin K expression, with only focal weak staining for SMA and absence of melanocytic markers (HMB45 and Melan-A). In the present case, the absence of HMB45 and Melan-A expression is considered atypical for classical PEComas. However, the immunophenotype of PEComa showing TFE3 immunoreactivity can be heterogeneous, and melanocytic markers may be patchy or entirely absent in a subset of cases. Importantly, recent studies have identified cathepsin K as a highly sensitive and potentially more reliable marker than HMB45 for PEComas, including cases showing TFE3 immunoreactivity. The combination of strong nuclear TFE3 expression and intense cytoplasmic cathepsin K staining in our case supports the possibility of a PEComa with TFE3 immunoreactivity, even in the absence of melanocytic marker expression. This profile raised the possibility of a PEComa showing TFE3 immunoreactivity, an uncommon immunophenotypic presentation that has been reported in urinary bladder PEComas [4, 6]. In previously reported bladder PEComa series, cathepsin K has been consistently expressed in most cases and has been proposed as a useful diagnostic marker, whereas melanocytic markers can be variable or even absent, potentially leading to diagnostic pitfalls [4, 6, 13, 14]. Moreover, TFE3 immunohistochemical positivity does not necessarily indicate a molecularly confirmed TFE3 rearrangement, and rearrangement status may only be clarified by FISH or sequencing [4, 6, 15]. Alveolar soft part sarcoma (ASPS) should also be considered in the differential diagnosis because ASPS may demonstrate TFE3 positivity and overlapping morphologic features with PEComa. However, the present case lacked significant cytologic atypia and vascular invasion, which are less typical of ASPS. In addition, the strong cathepsin K expression and the overall morphologic and immunophenotypic findings were considered more suggestive of PEComa showing TFE3 immunoreactivity. Nevertheless, ASPS cannot be completely excluded in the absence of molecular confirmation [6, 14, 15]. Therefore, comprehensive morphologic evaluation together with a broad immunohistochemical panel remains essential to distinguish PEComa from its mimics in the setting of a hypervascular bladder tumor. To contextualize our findings, we summarized the clinicopathologic and molecular features of previously reported bladder PEComas, with an emphasis on TFE3 status, immunophenotype, treatment, and outcome (Table 1). Table 1Clinicopathologic and molecular features of previously reported PEComas of the urinary bladder, with emphasis on TFE3 statusAuthor (Year)Cases (TFE3+)Age (y)Sex (M/F)Size (cm)Key IHC findingsTFE3 status / FusionOutcomeSangoi et al. (2025)21 (8 FISH+)17–818 / 13NRCathepsin K+ (100%); Melan-A/HMB45 variableSFPQ–TFE3 (n = 7); NONO–TFE3 (n = 1); TFE3 IHC + in 9/19Metastasis in 5/7 with follow-upWu et al. (2021)7 (0 FISH+)26–782 / 51.5–6.9HMB45+ (7/7); SMA+ (5/7)None2 recurrences; 1 deathChen et al. (2018)1 (1 FISH+)270/13.0Cathepsin K+; SMA (patchy+); Melan-A−SFPQ–TFE3 (NTRK3–SPTA1 co-alteration)No recurrenceNeumann et al. (2021)11 (5/8 FISH+)24–612 / 90.5–12Cathepsin K+ (10/11); Melan-A/HMB45 variableTFE3 rearranged (FISH+); fusion partner not reported2 malignant cases (1 death; 1 recurrence, alive, NED)Russell et al. (2011)1 (1 FISH+)271/04.2 → 2.5→multiple recurrencesHMB45+; SMA−Xp11 TFE3 rearrangementMetastatic disease with multiple recurrencesVannucchi et al. (2020)1 (1 FISH+)661/02.0HMB45+; SMA−FISH+; fusion partner not reportedNo recurrence at 3 yearsPEComa Perivascular epithelioid cell tumor, IHC Immunohistochemistry, FISH Fluorescence in situ hybridization, TFE3 Transcription factor E3, NR Not reported, NED No evidence of disease Table 1Clinicopathologic and molecular features of previously reported PEComas of the urinary bladder, with emphasis on TFE3 statusAuthor (Year)Cases (TFE3+)Age (y)Sex (M/F)Size (cm)Key IHC findingsTFE3 status / FusionOutcomeSangoi et al. (2025)21 (8 FISH+)17–818 / 13NRCathepsin K+ (100%); Melan-A/HMB45 variableSFPQ–TFE3 (n = 7); NONO–TFE3 (n = 1); TFE3 IHC + in 9/19Metastasis in 5/7 with follow-upWu et al. (2021)7 (0 FISH+)26–782 / 51.5–6.9HMB45+ (7/7); SMA+ (5/7)None2 recurrences; 1 deathChen et al. (2018)1 (1 FISH+)270/13.0Cathepsin K+; SMA (patchy+); Melan-A−SFPQ–TFE3 (NTRK3–SPTA1 co-alteration)No recurrenceNeumann et al. (2021)11 (5/8 FISH+)24–612 / 90.5–12Cathepsin K+ (10/11); Melan-A/HMB45 variableTFE3 rearranged (FISH+); fusion partner not reported2 malignant cases (1 death; 1 recurrence, alive, NED)Russell et al. (2011)1 (1 FISH+)271/04.2 → 2.5→multiple recurrencesHMB45+; SMA−Xp11 TFE3 rearrangementMetastatic disease with multiple recurrencesVannucchi et al. (2020)1 (1 FISH+)661/02.0HMB45+; SMA−FISH+; fusion partner not reportedNo recurrence at 3 yearsPEComa Perivascular epithelioid cell tumor, IHC Immunohistochemistry, FISH Fluorescence in situ hybridization, TFE3 Transcription factor E3, NR Not reported, NED No evidence of disease Clinicopathologic and molecular features of previously reported PEComas of the urinary bladder, with emphasis on TFE3 status PEComa Perivascular epithelioid cell tumor, IHC Immunohistochemistry, FISH Fluorescence in situ hybridization, TFE3 Transcription factor E3, NR Not reported, NED No evidence of disease From a management perspective, complete surgical excision remains the mainstay treatment for bladder PEComa, and transurethral resection may be sufficient for small, localized lesions. Although TFE3-rearranged PEComas have been reported to exhibit aggressive behavior in some cases, risk stratification in bladder PEComa remains challenging and should integrate tumor size, mitotic activity, necrosis, and invasion. In our patient, the small tumor size, absence of necrosis, and low Ki-67 index suggested a low-risk profile, and no recurrence has been detected during short-term follow-up. Limitations We acknowledge that the lack of molecular confirmation, such as fluorescence in situ hybridization (FISH) or next-generation sequencing to detect TFE3 gene rearrangement, is a significant limitation of this report. Due to the patient’s rapid recovery and objective institutional constraints at the time, molecular validation was not performed. Nevertheless, the striking morphological features and the distinct 'TFE3+/Cathepsin K+/Syn-' immunophenotype were considered suggestive of PEComa with TFE3 immunoreactivity and offer valuable insights into the diagnostic pitfalls of hypervascular bladder tumors.Our case underscores that PEComa should be included in the differential diagnosis of hypervascular bladder tumors in adolescents, particularly when imaging suggests paraganglioma but biochemical evaluation is negative. Conclusion Urinary bladder PEComa is a rare entity that may closely mimic paraganglioma on imaging because of its hypervascular nature. This case illustrates that PEComa showing TFE3 immunoreactivity can present in adolescent patients and be clinically misdiagnosed despite the absence of typical endocrine manifestations. Awareness of this diagnostic pitfall and careful integration of imaging, histopathology, and immunohistochemistry are essential for accurate diagnosis. PEComa should be included in the differential diagnosis of hypervascular bladder tumors, particularly when biochemical evaluation for paraganglioma is negative.